Barclays analyst Matt Miksic raised the firm’s price target on ZimVie to $11 from $7 but keeps an Underweight rating on the shares after its Q2 results. The analyst is more positive given the slower declines in ZimVie’s Spine business, though the firm remains concerned about the contracting growth combined with the company’s relatively high debt levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZIMV: